Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
December 13, 2006

Introgen Awarded European Patent

  • Introgen Therapeutics was granted a broad patent by the European Patent Office that relates to the production of purified adenoviral compositions that are commercially scaleable and can be readily validated for regulatory purposes. This patent complements three previously issued U.S. patents related to the production of adenoviral vectors.

    "This patent is the European complement to our existing U.S. adenovirus production/purification technology,” David L. Parker, Ph.D., Introgen's senior vp of intellectual property. “It is of particular importance in that it covers the production of adenoviruses of commercial scale, quantity, and purity, regardless of whether the adenovirus is used as a delivery system for therapeutic genes, used directly as a therapeutic agent, used as a vaccine or vaccine component, or simply used for research and development purposes."

  • You’re all set! Thank you for subscribing to GEN Highlights.